PETRI DISH PERSPECTIVES

Burma | Chicago
Scientist 🥼🧪🔬
Covering biotech, pharma, and healthcare companies shaping the world 🧬🏥🌎

Stream new episodes every THURSDAY!

https://linktr.ee/maneadkhin

#biotech #pharma #healthcare #podcast #petridishperspectives

All Episodes

PETRI DISH PERSPECTIVES

Episode 41: Gene Therapies

February 05, 2026 • Manead Khin • Season 1 • Episode 41

0:00 | 25:36

Send a text

What if medicine could fix disease at its source… by rewriting the genetic code itself?

In this episode of Petri Dish Perspectives, we dive into the incredible story of gene therapy, one of the most ambitious and transformative frontiers in modern medicine. From early scientific discoveries about DNA and viral delivery systems, to heartbreaking clinical setbacks that nearly shut the field down, and finally to today’s life-changing treatments for rare diseases, cancer, and genetic disorders, gene therapy represents decades of persistence, innovation, and scientific courage.

We explore the researchers who refused to give up, the breakthroughs that revived the field, and the biotech companies leading today’s gene therapy revolution, including pioneers developing CRISPR editing, viral vector platforms, and personalized cellular therapies. We also break down why gene therapy is reshaping the pharmaceutical industry and what the future may hold for curing previously untreatable diseases.

If you love biotech, cutting-edge science, and the stories behind medical breakthroughs, this is an episode you don’t want to miss.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

https://linktr.ee/maneadkhin

#GeneTherapy #Biotech #Genetics #CRISPR #CellTherapy #RareDisease #CancerResearch #Biopharma #MedicalInnovation #PrecisionMedicine #SciencePodcast #LifeSciences #DrugDevelopment #FutureOfMedicine #PetriDishPerspectives

Support the show

Hello and welcome to Petri Dish Perspectives, the podcast where we geek out about science and the companies shaping the future of healthcare. I’m your host, Manead, and I’m a PhD scientist by training, biotech storyteller by choice. With every new episode released on Thursday, my goal is to deliver digestible pieces of information on healthcare companies under 30 mins.

Today’s episode is about one of the boldest ideas ever attempted in medicine: gene therapy. The concept is simple but radical. Instead of treating symptoms, what if doctors could fix diseases at their genetic root? What if we could rewrite the biological code that causes illness?

For decades, gene therapy was considered science fiction. It sparked massive excitement, suffered devastating tragedies, nearly collapsed as a field, and then staged one of the greatest comebacks in modern biotechnology. Today, gene therapies are curing children born with fatal diseases, transforming cancer treatment, and opening the door to a future where medicine may permanently fix genetic disorders.

This is the story of gene therapy — from its scientific origins to its rise, fall, and dramatic resurgence.

Quick disclaimer, I give full credit to the original articles cited in the references in the transcript!

Grab a coffee or tea, settle in, and let’s jump in!

Segment 1: The Birth of Genetic Medicine

To understand gene therapy, we need to go back to the foundations of modern biology. In 1953, James Watson and Francis Crick described the structure of DNA, revealing that life is encoded in a double helix of genetic information. That discovery transformed biology into an information science. Scientists began realizing that diseases might be caused by errors in this genetic code.

By the 1970s, researchers started asking a revolutionary question. If disease is caused by faulty genes, could doctors replace them with healthy ones? Early pioneers such as Theodore Friedmann, often called the father of gene therapy, proposed using viruses as delivery vehicles. Viruses naturally inject genetic material into human cells, so scientists imagined reengineering viruses to deliver therapeutic genes instead of causing infection.

The idea captured enormous imagination, but technology lagged behind the theory. Scientists struggled to control gene delivery, prevent immune reactions, and ensure that inserted genes functioned properly.

Still, momentum grew. By the 1980s, advances in molecular cloning and recombinant DNA technology allowed researchers to manipulate genes more precisely. The stage was set for gene therapy to move from theory into clinical testing.

Segment 2: The First Human Gene Therapy and Early Optimism

In 1990, the first successful human gene therapy trial was conducted at the National Institutes of Health. The patient was a four-year-old girl, who suffered from adenosine deaminase severe combined immunodeficiency, or ADA-SCID. This disease prevents the immune system from functioning, leaving children vulnerable to infections.

Scientists extracted Ashanti’s immune cells, inserted a functional ADA gene using a modified virus, and reinfused the corrected cells back into her body. The results were encouraging. Her immune function improved, and the trial was hailed as proof that gene therapy could work.

The success sparked extraordinary excitement. Investors poured money into biotech startups focused on gene therapy. Pharmaceutical companies began funding research programs. Many believed cures for inherited diseases were just around the corner.

During the 1990s, multiple clinical trials launched targeting diseases like cystic fibrosis, hemophilia, and muscular dystrophy. The field became one of the hottest areas in biotechnology.

But behind the enthusiasm, the science remained fragile.

Segment 3: The Tragedy That Shook the Field

The optimism collapsed in 1999 following a tragedy that would haunt gene therapy for years. An eighteen-year-old patient enrolled in a clinical trial for ornithine transcarbamylase deficiency, a metabolic disorder. The trial used an adenovirus vector to deliver a corrective gene.

Shortly after treatment, Jesse experienced a massive immune reaction to the viral vector. Within days, he died from multiple organ failure.

The event shocked the scientific and regulatory communities. Investigations revealed concerns about trial oversight, risk communication, and vector safety. Public trust in gene therapy plummeted. Funding evaporated. Many companies abandoned their programs entirely.

For more than a decade, gene therapy was viewed as a cautionary tale of scientific overconfidence. Yet a small group of researchers continued working quietly, improving vector design and understanding immune responses.

Their persistence would eventually change everything.

One of the most important figures was James Wilson at the University of Pennsylvania. Ironically, Wilson had been connected to the Gelsinger trial, but instead of abandoning gene therapy, he dedicated his career to making it safer. Wilson became one of the leading pioneers of adeno associated virus, or AAV, vector development. His laboratory systematically identified safer viral subtypes and helped create the delivery platforms that would later power modern gene therapy breakthroughs.

Another key figure was Katherine High, a hematologist and molecular geneticist who spent decades studying hemophilia. High believed gene therapy could permanently correct blood clotting disorders. Working first at the Children’s Hospital of Philadelphia and later helping found Spark Therapeutics, she led clinical trials that demonstrated gene therapy could restore clotting factor production in hemophilia patients. Her work provided some of the earliest convincing proof that gene therapy could produce durable, long term results.

Meanwhile, Jean Bennett, an ophthalmologist and geneticist, focused on inherited blindness. Together with her husband Albert Maguire, Bennett spent years developing retinal gene delivery methods. Their persistence ultimately led to Luxturna, the first FDA approved gene therapy for an inherited disease, restoring vision in patients who were progressively going blind.

Another important contributor was Luigi Naldini, an Italian scientist who revolutionized the use of lentiviral vectors. Naldini demonstrated that lentiviruses could deliver genes into stem cells safely and effectively. His work became foundational for gene therapies targeting blood disorders and immune diseases.

These scientists and their collaborators kept gene therapy alive during its darkest period. They rebuilt trust through rigorous experimentation, careful clinical design, and transparent safety monitoring. Without their persistence, the modern gene therapy revolution likely would never have happened.

Segment 4: The Technological Breakthroughs That Enabled the Comeback

The rebirth of gene therapy was not just a scientific story. It was also driven by visionary scientists, physician entrepreneurs, and biotech leaders who transformed fragile academic discoveries into viable medical products.

A central figure in this resurgence was Katherine High, who transitioned from academic medicine into industry leadership. At Spark Therapeutics, she helped guide the development and commercialization of Luxturna, demonstrating that gene therapy could succeed not only in research labs but also in the pharmaceutical marketplace.

Another major leader was Jeffrey Leiden, a physician scientist who became CEO of AveXis. Leiden helped accelerate the development of Zolgensma, a gene therapy for spinal muscular atrophy. Under his leadership, AveXis rapidly advanced clinical trials and manufacturing capabilities, ultimately leading to the therapy’s acquisition by Novartis and global launch. Zolgensma showed that gene therapy could treat devastating pediatric diseases with a single treatment.

In oncology, Carl June at the University of Pennsylvania became one of the pioneers of CAR T cell therapy. June’s research demonstrated that immune cells could be genetically reprogrammed to attack cancer. His early clinical trials showed unprecedented remission rates in leukemia patients, laying the scientific foundation for therapies such as Kymriah.

Another influential figure was Donald Kohn at UCLA, who helped develop stem cell based gene therapies for immune deficiencies. Kohn’s work demonstrated that genetically corrected stem cells could permanently rebuild immune systems in children born with severe genetic diseases.

At the same time, the gene editing revolution was being shaped by researchers like Jennifer Doudna and Emmanuelle Charpentier, whose discovery of CRISPR Cas9 created a powerful tool for directly editing DNA. Their work dramatically expanded gene therapy beyond gene replacement into precise genetic correction.

From the industry side, leaders such as Moncef Slaoui, who helped guide early gene therapy investments at GlaxoSmithKline, and George Yancopoulos at Regeneron, who championed advanced biologics and genetic medicine platforms, helped integrate gene therapy into mainstream pharmaceutical strategy.

Together, these individuals did more than advance science. They built companies, secured regulatory approvals, developed manufacturing infrastructure, and convinced investors and regulators that gene therapy could become a sustainable medical industry.

By the early 2010s, their combined efforts transformed gene therapy from a struggling experimental concept into one of the most promising therapeutic modalities in modern medicine.

Segment 5: The First Commercial Gene Therapy Successes

The modern era of gene therapy truly began in 2017. That year, the FDA approved Luxturna, developed by Spark Therapeutics. Luxturna treats a rare inherited form of blindness by delivering a functional copy of the RPE65 gene directly into retinal cells. Patients who were previously losing vision regained the ability to see in low light.

Later that year, Novartis launched Kymriah, the first CAR-T cell therapy. CAR-T therapies involve genetically modifying a patient’s immune cells to recognize and attack cancer. Kymriah transformed treatment for certain leukemias and lymphomas and demonstrated that gene modification could cure aggressive cancers.

In 2019, Novartis introduced Zolgensma, a gene therapy for spinal muscular atrophy. Often described as one of the most expensive drugs ever developed, its single-dose treatment can save infants from a fatal neuromuscular disease. Zolgensma became a symbol of both gene therapy’s power and its economic challenges.

When launched in May 2019, Novartis' Zolgensma was priced at $2.125 million per dose. As a one-time gene therapy for children under two with spinal muscular atrophy (SMA), it was at the time, and upon its launch, recognized as one of the most expensive drugs in the world.

Segment 6: The Companies Leading the Gene Therapy Revolution

Several companies have emerged as dominant forces in the gene therapy landscape. Spark Therapeutics pioneered ocular gene therapy before being acquired by Roche. Bluebird Bio became a leader in genetic blood disorder therapies, focusing on sickle cell disease and beta-thalassemia.

Sarepta Therapeutics has focused heavily on Duchenne muscular dystrophy, developing gene therapies targeting muscle regeneration. CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics are advancing gene editing approaches that allow precise DNA correction rather than gene replacement.

Vertex Pharmaceuticals has also entered the space, collaborating with CRISPR Therapeutics to develop gene-editing therapies for sickle cell disease. Meanwhile, large pharmaceutical companies like Novartis, Pfizer, Roche, and Johnson & Johnson have invested billions to build internal gene therapy pipelines.

The field has evolved into one of the most competitive and high-investment sectors in biotechnology.

Segment 7: The Controversies and Challenges of Gene Therapy

Despite its breakthroughs, gene therapy faces major challenges. The most obvious is cost. Many gene therapies are priced in the millions of dollars per treatment, raising ethical and reimbursement questions. Healthcare systems struggle to evaluate therapies that deliver lifetime benefits after a single dose.

Safety remains another concern. Some gene therapies have been associated with immune reactions, liver toxicity, and rare cancer risks linked to genetic insertion. Regulators continue balancing innovation with patient safety.

Manufacturing is also extremely complex. Producing viral vectors at scale remains difficult, creating supply limitations and high development costs.

These challenges highlight that gene therapy is still evolving, both scientifically and economically.

Segment 8: Gene Therapy in Popular Culture and Public Awareness

Gene therapy has increasingly entered mainstream conversation. Stories of children cured of inherited diseases have captured public imagination. Media coverage often portrays gene therapy as futuristic medicine capable of curing nearly any condition.

The rise of CRISPR has further elevated public attention, especially after controversial gene-editing experiments in human embryos sparked global ethical debates. Gene therapy is now part of conversations about longevity, personalized medicine, and even potential human enhancement.

Segment 9: What’s Next for Gene Therapy

The future of gene therapy is expanding rapidly. Scientists are working toward in vivo gene editing, where DNA is corrected directly inside the body without removing cells. Researchers are also developing gene therapies for common diseases such as cardiovascular disorders and neurodegenerative conditions.

New delivery technologies, including lipid nanoparticles and non-viral platforms, could improve safety and reduce costs. Advances in AI-driven protein engineering may accelerate vector design and therapeutic optimization.

Many experts believe gene therapy could eventually shift medicine from chronic disease management to permanent cures.

Conclusion

Gene therapy represents one of the most dramatic scientific journeys in modern medicine. It began as an ambitious idea, suffered devastating setbacks, and ultimately reemerged as one of the most transformative healthcare technologies of our time.

From curing inherited blindness to treating aggressive cancers, gene therapy is redefining what medicine can accomplish. The field still faces obstacles, but its trajectory suggests we are entering an era where diseases once considered untreatable may become curable.

And that is the promise of gene therapy: rewriting the code of life itself.

This has been Petri Dish Perspectives. I’m Manead. Thanks for listening. See you next Thursday. Good bye.

References

Manead Khin

Host